Specificity concerns with antibodies for receptor mapping.

Therapeutic antibodies directed at G protein-coupled receptors. MAbs (2010) 1.41

The effect of erythropoietin on normal and neoplastic cells. Biologics (2012) 0.98

KATP channel subunits in rat dorsal root ganglia: alterations by painful axotomy. Mol Pain (2010) 0.94

Initiation and termination of DNA replication during S phase in relation to cyclins D1, E and A, p21WAF1, Cdt1 and the p12 subunit of DNA polymerase δ revealed in individual cells by cytometry. Oncotarget (2015) 0.85

Editorial: Antibody can get it right: confronting problems of antibody specificity and irreproducibility. Mol Endocrinol (2014) 0.83

'Altered' mesenteric artery SK(Ca) : functional implications? Br J Pharmacol (2011) 0.83

Antibodies for immunolabeling by light and electron microscopy: not for the faint hearted. Histochem Cell Biol (2014) 0.79

A putative role for platelet-derived PPARγ in vascular homeostasis demonstrated by anti-PPARγ induction of bleeding, thrombocytopenia and compensatory megakaryocytopoiesis. J Biotechnol (2010) 0.75

β1-adrenergic receptor O-glycosylation regulates N-terminal cleavage and signaling responses in cardiomyocytes. Sci Rep (2017) 0.75

Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific. Naunyn Schmiedebergs Arch Pharmacol (2008) 1.97

Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol (2009) 1.61

Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice. Naunyn Schmiedebergs Arch Pharmacol (2008) 1.47

Where is TRPV1 expressed in the bladder, do we see the real channel? Naunyn Schmiedebergs Arch Pharmacol (2009) 1.23

Analyzing the validity of GalR1 and GalR2 antibodies using knockout mice. Naunyn Schmiedebergs Arch Pharmacol (2009) 1.20

Lack of specificity of antibodies directed against human beta-adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol (2009) 1.15

Should we be cautious on the use of commercially available antibodies to dopamine receptors? Naunyn Schmiedebergs Arch Pharmacol (2008) 1.02

Vorinostat. Nat Rev Drug Discov (2007) 2.83

Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res (2006) 2.58

Abatacept. Nat Rev Drug Discov (2006) 2.13

Pegloticase. Nat Rev Drug Discov (2011) 1.76

Vemurafenib. Nat Rev Drug Discov (2011) 1.68

Tetrabenazine. Nat Rev Drug Discov (2009) 1.60

Eculizumab. Nat Rev Drug Discov (2007) 1.56

Dabigatran etexilate. Nat Rev Drug Discov (2008) 1.41

Sipuleucel-T. Nat Rev Drug Discov (2010) 1.37

Tocilizumab. Nat Rev Drug Discov (2009) 1.36

Effect of decompressive craniectomy on intracranial pressure and cerebrospinal compensation following traumatic brain injury. J Neurosurg (2008) 1.35

Cabazitaxel. Nat Rev Drug Discov (2010) 1.34

Denosumab. Nat Rev Drug Discov (2010) 1.31

Cetuximab. Nat Rev Drug Discov (2004) 1.31

Panitumumab. Nat Rev Drug Discov (2006) 1.31

Everolimus. Nat Rev Drug Discov (2009) 1.29

Liraglutide. Nat Rev Drug Discov (2010) 1.27

Dasatinib. Nat Rev Drug Discov (2006) 1.25

Azacitidine. Nat Rev Drug Discov (2005) 1.23

Enfuvirtide. Nat Rev Drug Discov (2003) 1.22

Daptomycin. Nat Rev Drug Discov (2003) 1.22

Erlotinib hydrochloride. Nat Rev Drug Discov (2005) 1.22

Asenapine. Nat Rev Drug Discov (2009) 1.21

Ipilimumab. Nat Rev Drug Discov (2011) 1.20

Duloxetine hydrochloride. Nat Rev Drug Discov (2004) 1.17

Vismodegib. Nat Rev Drug Discov (2012) 1.16

Eribulin mesylate. Nat Rev Drug Discov (2011) 1.14

Oxaliplatin. Nat Rev Drug Discov (2004) 1.14

Tolvaptan. Nat Rev Drug Discov (2009) 1.13

Ivacaftor. Nat Rev Drug Discov (2012) 1.12

Febuxostat. Nat Rev Drug Discov (2009) 1.12

Golimumab. Nat Rev Drug Discov (2009) 1.11

Lapatinib. Nat Rev Drug Discov (2007) 1.10

Bevacizumab. Nat Rev Drug Discov (2004) 1.09

Lacosamide. Nat Rev Drug Discov (2008) 1.09

Ranibizumab. Nat Rev Drug Discov (2006) 1.08

Sunitinib maleate. Nat Rev Drug Discov (2006) 1.07

Crizotinib. Nat Rev Drug Discov (2011) 1.05

Plerixafor. Nat Rev Drug Discov (2009) 1.04

Brentuximab vedotin. Nat Rev Drug Discov (2012) 1.04

Aflibercept. Nat Rev Drug Discov (2012) 1.04

Exenatide. Nat Rev Drug Discov (2005) 1.02

Pazopanib. Nat Rev Drug Discov (2010) 1.02

Ustekinumab. Nat Rev Drug Discov (2009) 1.02

Decitabine. Nat Rev Drug Discov (2006) 1.02

Varenicline. Nat Rev Drug Discov (2006) 0.99

Gefitinib. Nat Rev Drug Discov (2003) 0.99

Pregabalin. Nat Rev Drug Discov (2005) 0.98

Teriparatide. Nat Rev Drug Discov (2003) 0.98

Certolizumab pegol. Nat Rev Drug Discov (2008) 0.98

Belatacept. Nat Rev Drug Discov (2011) 0.96

Ruxolitinib. Nat Rev Drug Discov (2012) 0.96

Telavancin. Nat Rev Drug Discov (2009) 0.94

Dronedarone. Nat Rev Drug Discov (2009) 0.93

Ezogabine (retigabine). Nat Rev Drug Discov (2011) 0.92

Ecallantide. Nat Rev Drug Discov (2010) 0.91

Posaconazole. Nat Rev Drug Discov (2007) 0.91

Tafamidis. Nat Rev Drug Discov (2012) 0.91

Tigecycline. Nat Rev Drug Discov (2005) 0.91

Surgery for brain edema. Neurosurg Focus (2007) 0.91

Prasugrel. Nat Rev Drug Discov (2009) 0.90

Pegaptanib sodium. Nat Rev Drug Discov (2005) 0.90

Memantine hydrochloride. Nat Rev Drug Discov (2004) 0.88

Fresh from the pipeline. Ticagrelor. Nat Rev Drug Discov (2011) 0.87

Telbivudine. Nat Rev Drug Discov (2007) 0.87

Romiplostim. Nat Rev Drug Discov (2008) 0.86

Alvimopan. Nat Rev Drug Discov (2008) 0.86

Sitagliptin. Nat Rev Drug Discov (2007) 0.86

Velaglucerase alfa. Nat Rev Drug Discov (2010) 0.85

Roflumilast. Nat Rev Drug Discov (2010) 0.85

Tipranavir. Nat Rev Drug Discov (2005) 0.85

Quadrivalent human papillomavirus recombinant vaccine. Nat Rev Drug Discov (2006) 0.85

Aripiprazole. Nat Rev Drug Discov (2003) 0.84

Differential cyclin E expression in human in-stent stenosis smooth muscle cells identifies targets for selective anti-restenosis therapy. Cardiovasc Res (2003) 0.83

Pirfenidone. Nat Rev Drug Discov (2011) 0.83

Pemetrexed disodium. Nat Rev Drug Discov (2004) 0.83

Belimumab. Nat Rev Drug Discov (2011) 0.83

Pasireotide. Nat Rev Drug Discov (2012) 0.81

Ofatumumab. Nat Rev Drug Discov (2010) 0.81

Entecavir. Nat Rev Drug Discov (2005) 0.81

Efalizumab. Nat Rev Drug Discov (2004) 0.81

Ranolazine. Nat Rev Drug Discov (2006) 0.81

Inhaled aztreonam. Nat Rev Drug Discov (2010) 0.81

Meningococcal group A, C, Y and W-135 conjugate vaccine. Nat Rev Drug Discov (2010) 0.80

Eplerenone. Nat Rev Drug Discov (2003) 0.80

Abiraterone acetate. Nat Rev Drug Discov (2011) 0.80

Natalizumab. Nat Rev Drug Discov (2005) 0.80

Bendamustine. Nat Rev Drug Discov (2008) 0.79

Fresh from the pipeline: Ramelteon. Nat Rev Drug Discov (2005) 0.79

Lisdexamfetamine dimesylate. Nat Rev Drug Discov (2007) 0.78

Rasagiline. Nat Rev Drug Discov (2005) 0.78

Clofarabine. Nat Rev Drug Discov (2005) 0.78

Galsulfase. Nat Rev Drug Discov (2006) 0.78

Omalizumab. Nat Rev Drug Discov (2004) 0.78

Atazanavir sulphate. Nat Rev Drug Discov (2003) 0.77

Telithromycin. Nat Rev Drug Discov (2004) 0.77

Tiotropium bromide. Nat Rev Drug Discov (2004) 0.77

Nelarabine. Nat Rev Drug Discov (2006) 0.77

Atomoxetine hydrochloride. Nat Rev Drug Discov (2004) 0.77

Vernakalant. Nat Rev Drug Discov (2010) 0.77